47 results about "Aroa" patented technology

Live-attenuated vaccines against Edwardsiella ictaluri or against Pasteurella piscicida are disclosed. Both vaccines are incapable of reversion to virulence, because both are made by deletion mutations in the aroA gene, the purA gene, or both. These vaccines may be used not only to vaccinate fish against Edwardsiella ictaluri or Pasteurela piscicida, but also to serve as vectors to present antigens from other pathogens to the fish, thereby serving as vaccines against other pathogens as well, with no risk of infection by reversion to the virulent form of the pathogen in which the antigen occurs naturally.

The invention discloses a construction method of a genetic engineering strain for producing shikimic acid. The method comprises the following steps of: 1, constructing an escherichia coli strain of which the aroA gene is knocked out; 2, constructing a recombinant expression plasmid pAR63 containing key enzyme genes aroGFBR, aroE, aroB, aroD, tktA and ppsA in the metabolic pathway of the shikimic acid, so that the genes are subjected to transcriptional control of a tryptophan promoter Ptrp; and 3, transferring the recombinant expression plasmid pAR63 into the escherichia coli strain of which the aroA gene is knocked out to obtain a production strain for expressing the shikimic acid. In the method, the aim of interrupting the metabolism of the shikimic acid is fulfilled by the knock-out of the single gene aroA, a small number of genes are knocked out, the operating difficulty is low, and the expression of the genes is in the state of starting and stopping automatically and is started automatically in the middle and late period without the induction of inducers, so the possibility of adding toxic substances into a culture medium is reduced, and the shikimic acid has high yield.

The present invention provides a biologically pure isolate of the genus Salmonella having a disruption of at least one gene selected from the group consisting of aroA, rfaH, and thyA, as well as a method of treating cancer including the step of administering such a Salmonella to a subject in need thereof.

The invention discloses a method for detecting a roundup ready protein G2-aroA and a special enzyme linked immune kit. The enzyme linked immune kit contains independently packaged anti-G2-aroA protein monoclonal antibody; the amino acid sequence of the G2-aroA protein refers to sequence 9 in a sequence list; and the monoclonal antibody is generated by a hybridoma cell strain AntiG2-5F11 CGMCC No.5772. The enzyme linked immune kit provided by the invention can be used for qualitatively or quantitatively detecting the expression of the roundup ready protein G2-aroA in transgenic plants such as corn, and has the advantages of rapidness, sensitiveness and strong specificity.

The present invention discloses a fusion gene of compound antibody type with glyphosate and glufosinate, encoded protein and application thereof, The fusion gene composes of a glyphosate-tolerant encoded-protein gene and a glufosinate-tolerant encoded-protein gene. The glyphosate encoded gene is one of the following: CP4, aroA, G7, G10, GOX or GAT; the glufosinate encoded gene is bar or pat. The compound protein can give compound antibodies to the plants, glyphosate and glufosinate; it can be used to produce transgene plants with the antibody property of glyphosate and glufosinate. The provided compound protein with antibody properties of glyphosate and glufosinate can be used in herbicides for monocotyledonous plants and dicotyleons; it is mainly used in herbicides for insect resistant corn, rice, soybean, wheat and rape.

A bivalent plant expression carrier for culturing high anti-roundup transfer gene plant contains G2-aroA and gat. It has better anti-roundup performance and can be used to culture various high anti-roundup transfer gene plants.

The invention discloses a glyphosate-resistant fusion gene, coding protein and application thereof, the fusion gene consists of the EPSPS protein encoding gene and the glyphosate N-acetyltransferase or glyphosate oxidase encoding gene; the EPSPS protein is one of the following: CP4, aroA, G7 or G10; glyphosate N-acetyltransferase encoding gene is GAT, and glyphosate oxidase encoding gene is GOX. Compared with glyphosate-resistant protein, the glyphosate-resistant fusion gene and the coding protein have the following advantages: the glyphosate-resistant fusion gene and the coding proteincan be resistant to glyphosate by two different tolerance mechanisms; two glyphosate tolerance mechanisms and high glyphosate resistance of transgenic plants can be conferred by one gene. The glyphosate-resistant fusion protein can be used in the anti-glyphosate of monocotyledonous and dicotyledonous plants, and is mainly used for herbicide-resistant insect-resistant maize, rice, soybean, wheat and rape.

The invention belongs to the technical field of vaccine preparation of animal gene engineering and particularly relates to the construction of a Bordetella bronchiseptica aroA (5-enolpyruvyl-shikimate-3-phosphate synthase) gene deleted bacterial strain, and the preparation and application of a gene deleted vaccine. The Bordetella bronchiseptica gene deleted bacterial strain QH0814DeltaaroA is preserved in the China Center for Type Culture Collection with the collection number of CCTCCNO: M208018. The deletion of 5-enolpyruvyl-shikimate-3-phosphate synthase (aroA) gene with the full length of 1340bp causes an obstacle when the bacterial strain metabolizes aromatic amino acid. The invention prepares the Bordetella bronchiseptica gene deleted vaccine by using the gene deleted bacterial strain. The invention also discloses the application of the gene deleted bacterial strain in preparing the Bordetella bronchiseptica gene deleted vaccine (attenuated live vaccine).

The invention belongs to the technical field of animal bacteriology and vaccine genetic engineering preparation, and relates to a resistance mark-free recombinant bordetella bronchiseptica strain for expression of a pig toxaigenic pasteurella multocida toxA gene fragment, and its vaccine containing the resistance mark-free recombinant bordetella bronchiseptica strain, a preparation method and a use. The resistance mark-free recombinant bordetella bronchiseptica strain QH0814 delta aroA/toxA-N for expression of the pig toxaigenic pasteurella multocida toxA gene fragment does not contain a 5-enolpyrul-shikimate-3-phosphate synthase aroA gene of bordetella bronchiseptica, and contains the pig toxaigenic pasteurella multocida toxA gene fragment. The invention also discloses the preparation method of the resistance mark-free recombinant bordetella bronchiseptica strain and the vaccine use. The genetic engineering vaccine can stimulate a pig to produce a protective immune response for resisting pig toxaigenic pasteurella multocida and a wild strain of pig bordetella bronchiseptica, and can effectively prevent the double infection caused by pig toxaigenic pasteurella multocida and pig bordetella bronchiseptica.

The invention relates to a Bordetella bronchiseptica gene deletion strain, vaccine prepared from the Bordetella bronchiseptica gene deletion strain and application of the strain. The aroA gene deletion strain, namely aroA-LY1 (Bordetella bronchiseptica), is preserved in the China Center for Type Culture Collection (CCTCC) on 23 December 2011, and the preservation number is CCTCCNO: M 2011479. The Bordetella bronchiseptica gene deletion strain disclosed by the invention has excellent immune protection efficacy and weak toxicity without any adverse side effect on immunized pigs and is safer compared with the traditional vaccine. Therefore, the vaccine which is prepared from the gene deletion strain built by a parent strain has wide market application prospect. In addition, the Bordetella bronchiseptica gene deletion strain disclosed by the invention retains the immune protective efficacy aiming at Bordetella bronchiseptica infection, and has clear genetic background and stable characteristics, so that the Bordetella bronchiseptica gene deletion strain has better biosecurity. The Bordetella bronchiseptica gene deletion strain disclosed by the invention does not contain a resistance tag and totally accords with the biological security requirement of vaccine.

A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a polynucleotide construct operably encoding an a Fra-1 protein, such as a polyubiquitinated human Fra-1 protein, and IL-18, such as human IL-18, in a pharmaceutically acceptable carrier. In a preferred embodiment, the polynucleotide construct is operably incorporated in an attenuated bacterial vector, such as an attenuated Salmonella typhimurium, particularly a doubly attenuated aroA- dam- S. typhimurium. Transformed host cells, methods of inhibiting tumor growth, of vaccinating a patient against cancer, and of delivering genetic material to a mammalian cell in vivo are also described.

The invention discloses a primer pair for detecting G2-aroA gene-modified herbicide-tolerant corn G11105E-823C. The primer pair for detecting the G2-aroA gene-modified herbicide-tolerant corn G11105E-823C provided by the invention is concretely composed of two DNA molecule single chains represented by sequence 1 and sequence 2 in a sequence table. Experiments show whether corns to be detected are the G2-aroA gene-modified herbicide-tolerant corn G11105E-823C can be detected through a PCR method by using the primer pair, and the method is high in accuracy rate, strong in specificity and high in sensibility.

The invention discloses a gene aroAS001 for encoding 5-enolpyruvyl-shikimate-3-phosphate synthase, and an application of the gene, wherein the base sequence of the gene is represented by SEQ ID No.3; the gene is suitable for enhancing glyphosate resistance of crops; specifically, gene aroAS001, and an expression vector or a cloning vector containing gene aroAS001, or strains containing the expression vector or cloning vector are transferred in the crops. The gene provided by the invention is an excellent glyphosate resistant gene, the aroA gene defect type strains transferred with the gene can grow in a culture medium containing lower than 400mM glyphosate; compared with other known EPSP (enolpyruvyl-shikimate-3-phosphate) synthase genes, the gene provided by the invention has significant glyphosate resistance and brings about unexpected beneficial effects.

The invention provides a salmonella typhimurium aroA and luxS double-gene-deleted strain and an attenuated vaccine prepared by the same. The salmonella typhimurium aroA and luxS double-gene-deleted strain is collected at China General Microbiological Culture Collection Center, and the collection number of the strain is CGMCC NO. 13736. The double-gene-deleted strain is obtained by deleting aroA and luxS genes by a Red homologous recombination method, so that toxicity is remarkably reduced, the prepared salmonella typhimurium double-gene-deleted attenuated vaccine is good in immunity maintenance, and the strain can be used for preparing the salmonella typhimurium double-gene-deleted attenuated vaccine for preventing and treating salmonella typhimurium infection.

The invention belongs to the technical field of microbial genetic engineering, and particularly relates to a cold-adapted I-type 5-enolpyruvoyl shikimic acid-3-phosphate synthase gene. The nucleotidesequence of the I-type 5-enolpyruvylshikimic acid-3-phosphate synthase (EPSPS) gene is as represented by SEQ ID NO: 1 in a sequence table, and the sequence of a protein encoded by the gene is as represented by SEQ ID NO: 2. The cold-adapted I-type 5-enolpyruvoyl shikimic acid-3-phosphate synthase gene is obtained by cloning according to an aroA gene conserved sequence of Isoptericola sp. GR1TH_0001 reported in Genbank. Biological tests prove that the enzyme has high tolerance to glyphosate and has unique low-temperature adaptability.

Methods of inhibiting the proliferation of Mycobacterium tuberculosis comprising contacting Mycobacterium tuberculosis with an effective amount of a polynucleotide complementary to an mRNA transcript expressed by Mycobacterium tuberculosis are provided. Typical methods of the invention utilize phosphorothioate modified antisense polynucleotides (PS-ODNs) against the mRNA of M. tuberculosis genes such as glutamine synthetase, aroA, ask, groES, and the genes of the Antigen 85 complex. Optionally, the methods employ multiple antisense polynucleotides targeting different Mycobacterium tuberculosis transcripts. In preferred embodiments of the invention, the antisense polynucleotides are complementary to the 5′ regions of the Mycobacterium tuberculosis transcripts.

A genetic deletion mutant live E. coli vaccine suitable for mass application to poultry, including chickens, is provided. Also provided is a safe and effective method to protect poultry against the ravages of Escherichia coli bacillosis infection and disease in which a live mutant aroA-gene deleted E. coli immunogen is administered to chickens, turkeys and the like via mass application routes such as coarse sprays and drinking water.

In a first aspect, the present invention relates to a mutated Salmonella strain comprising mutations in flagellin II genes, like the fliF gene, in particular, in addition the aroA gene, the IpxR gene, the pagP gene, the pagL gene, the ydiV gene and optionally the eptA gene and further optionally, the arnT gene. In a further aspect, immunogenic compositions comprising said Salmonella strain are provided optionally together with a pharmaceutically accepted carrier, diluent or effluent. Moreover, a method for producing outer membrane vesicles of Salmonella is provided, said method comprises the steps of cultivating the Salmonella strain according to the present invention and isolating the outer membrane vesicles accordingly. The present invention provides the bacteria or the outer membrane vesicles (OMVs) obtainable by the methods according to the present invention and its use as a transport moiety or as an immunogenic composition, like a vaccine or immunotherapy platform espedaily for therapeutic treatment of cancer of tissue or blood.

The invention provides an avian Escherichia coli vaccine strain. The avian Escherichia coli vaccine strain is a low virulent strain prepared by removing aroA genes on the basis of screening to obtainnovel avian pathogenic Escherichia coli O78. The avian Escherichia coli vaccine strain provided by the invention is prepared by deleting the aroA genes of an avian pathogenic Escherichia coli YBO78 strain with the preservation number of CCTCC M 2020382. The Escherichia coli vaccine YBO78-1 strain provided by the invention can be used by a conventional method, for example, the strain is applied ona large scale by economical and easy-to-operate spray and drinking water, and can also be applied by intramuscular injection or other modes.